What is Cardiogen 20MG

Cardiogen 20MG is a synthetic tetrapeptide bioregulator studied in research for its ability to selectively modulate cardiovascular tissue, regulate gene expression, and promote cardiac cell proliferation. It is intended exclusively for research use.

Regarding its chemical identity, Cardiogen has a molecular formula of C18H31N7O9 and a molecular weight of 489.5 g/mol. Its reported canonical sequence is Ala-Glu-Asp-Arg (AEDR). A confirmed CAS number is not available in open primary reference sources and is therefore omitted.

Its synonyms include Cardiogen.

Product for research use.

Mechanism of action of Cardiogen

Cardiogen acts primarily by regulating the expression of specific genes within the myocardium. It stimulates the proliferation of young cardiac cells and modulates apoptosis, ultimately leading to enhanced repair mechanisms in heart muscle tissues subjected to stress or ischemic conditions.

Pharmacokinetics and pharmacodynamics of Cardiogen

The pharmacokinetic behavior of Cardiogen is dominated by a very short plasma half-life due to rapid enzymatic degradation in systemic circulation. It quickly binds to specific cellular receptors in the cardiovascular system to initiate long-lasting intracellular signaling cascades.

Scientific evidence on Cardiogen

The available evidence on Cardiogen is preliminary and largely inconclusive, and should be interpreted with caution. The literature describes it as having been investigated for multiple indications in preclinical models.

One of the best-characterized research avenues is its application in models of ischemic heart disease and myocardial infarction, with the hypothesis of stimulating cardiac fibroblast proliferation without excessive scar tissue formation. Certain catalog claims regarding clinical cardiovascular restoration remain unverified.

Cardiogen applications in research

Ideal for (research context):
– In vitro and preclinical studies of its specific receptor pathways.
– Investigation of tissue repair, cell proliferation, and functional restoration in laboratory models.
– Comparative work with related peptides.

Not applicable for:
– clinical, diagnostic or therapeutic use.
– Any administration to humans or animals outside of an authorized research protocol.

Product for research use.

Cardiogen protocols in preclinical studies

The literature consulted does not include numerical doses from studies that can be cited for Cardiogen, so no trial schemes or quantities are specified.

The presentations of this product (20MG) refer only to the amount of lyophilized peptide per vial (or volume for liquids) and do not constitute a dosage recommendation. The design of any protocol, including concentrations and working volumes, is the responsibility of the researcher, based on their experimental objectives and the relevant primary literature.

Information provided exclusively for research purposes.

Reconstitution and manipulation of Cardiogen

As a general guideline for laboratory handling, lyophilized peptides such as Cardiogen are usually reconstituted with bacteriostatic water (sterile water with approximately 0.9% benzyl alcohol).

Add the solvent slowly down the side of the vial, letting it run over the lyophilized powder; avoid injecting the stream directly onto the powder.
Do not shake: gently rotate the vial until completely dissolved.
Adjust the solvent volume according to the desired working concentration, considering the 20MG contents of the vial.

These guidelines are for general technique and do not replace the internal procedures of each laboratory.

Cardiogen Stability and Storage

As a standard laboratory handling procedure for peptides:

Freeze-dried (unreconstituted): This is the most stable form. It is best preserved by freezing and protecting it from moisture and light for long-term storage.
Reconstituted: once in solution, the peptide is less stable and must be kept refrigerated, being used within a short period; for extended storage, freezing in aliquots is usually preferred.
Avoid repeated freeze-thaw cycles, as they can degrade the peptide.

Given that the molecule is characterized by rapid enzymatic degradation in biological media, careful cold chain management is especially relevant.

Documented Cardiogen security profile

The documented safety information in open sources for Cardiogen is limited and should be interpreted with caution, also considering that it is research material and not for clinical use.

Because it acts specifically on myocardial tissues, potential cardiovascular shifts such as altered heart rate or blood pressure could theoretically occur in vivo, though these are largely unverified in open primary sources.

Formal contraindications and adverse event rates are not available in the consulted literature, so no figures are reported.

Cardiogen in a comparative context

Cardiogen belongs to the Khavinson class of short peptides. Unlike longer, systemic growth factors, Cardiogen specifically targets the myocardium without inducing systemic hypertrophic effects, making it unique compared to general tissue repair peptides like BPC-157.

History and development of Cardiogen

Cardiogen was developed as part of the Khavinson peptide group originating from Russian research on short bioregulators. It was designed specifically to target cardiovascular aging and pathology, though extensive clinical trials in Western databases remain largely inconclusive or unconfirmed.